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medical therapies were randomized to receive either the EX-PRESS or a trabeculec-
tomy. Clinical outcomes included intraocular pressure (IOP), use of IOP lowering
medications and post-operative eye surgeries. The study follow-up was 5 years.
The economic perspective was the one of the French society. EX-PRESS cost was
not included. Patients were considered a success if they had an IOP less than or
equal to the success thresholds of 15 or 18 mmHg, without IOP lowering medica-
tions, and without having undergone further glaucoma surgery. Time to failure
was analyzed using a log rank test. Costs were discounted at a 3% rate. RESULTS: 78
patients were analyzed, 39 in each arm. EX-PRESS eyes had better IOP control at 1
(12.0 vs 13.9 mmHg; P0.02), 2 (11.9 vs 13.8 mmHg; P0.01) and 3 years (12.0 vs 13.5
mmHg; P0.04). The five-year failure rate was 41% for EX-PRESS versus 69% for
trabeculectomy (P0.005) using an 18 mmHg IOP target and 46% versus 77%
(P0.001) for 15 mmHg. At year 5, 41.0% of the EX-PRESS patients had an IOP
lowering drug prescription versus 53.9% for the trabeculectomy patients. EX-PRESS
patients received 0.85 IOP lowering medications versus 1.10 in the trabeculectomy
group. EX-PRESS patients required less needling (2 versus 5) and had fewer cataract
surgeries (5 versus 8). Without discounting, drug savings with EX-PRESS equaled
€277.00, €331.02 as a total. With a 3% discounting, the figures became €260.00 and
€342.97, respectively. CONCLUSIONS: At 5 years after surgery, EX-PRESS demon-
strated that it better controls IOP than trabeculectomy, resulting in post-operative
savings.
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OBJECTIVES: ST2 is a blood test that accurately risk stratifies patients with heart
failure (HF). This enables physicians to select high risk patients for intensive dis-
ease management (DM) programs. We evaluated the cost-effectiveness of ST2 in
patients discharged from hospital after an acute heart failure event.METHODS:We
developed a decision-analytic model to explore the 30-day mortality and cost out-
comes. A horizon of 30 days was used as a recognized hospital quality metric. We
compared two clinical scenarios: 1) HF patients did not enter DM programs; 2) only
patients with ST235 ng/ml entered DM programs. The clinical data came from the
Basel study, a prospective, blinded study of 591 HF subjects. We modeled the mor-
tality, the hypothetical reimbursement of ST2 testing, costs of DM and hospitaliza-
tions. A US health care system perspective was taken. A range of sensitivity anal-
yses and scenario analyses were performed. RESULTS: We simulated a cohort of
patients with a mean age of 78 years old over the 30-day period post discharge.
During that period there was 11.8% mortality and 20.1% all cause re-hospitalization
rates. We assumed a 26% reduction in mortality and a 21% reduction in re-hospi-
talization from intensive DM based on a peer-reviewed meta-analysis. The base
case showed that the ST2 strategy reduces lost life years by 0.217 with cost saving
of $1079 per tested patient when compared to no DM. Sensitivity analyses suggest
that the model is most sensitive to the cost of re-hospitalization and the cost and
effectiveness of the intensive DM program. CONCLUSIONS: Under a variety of
scenarios, prediction of 30-day HF risk with ST2, in order to select high risk patients
for enrollment into intensive DM programs, reduces mortality and is cost saving.
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OBJECTIVES: The objective was from a Turkish perspective to analyse the incre-
mental cost-effectiveness of Intrathecal baclofen therapy ( Tricumed™) compared
with medical treatment in adults for severe spasticity in Turkey. METHODS: We
compared the costs and health effects of intrathecal baclofen therapy with stan-
dard treatment only, from the health care perspective for a 1-year period. Health
effects were expressed in terms of an “ashworth score” as a year. The ashworth
score data was collected from the literature for both Intrathecal Baclofen Therapy
and medical treatment for severe spasticity. The cost of the treatments were cal-
culated based on the treatment guidelines for Turkish patient from the Turkish
health care payer’s perspectives. RESULTS: The annual average cost of Intrathecal
Baclofen Therapy per patient has been estimated to be €10357,27. On the other
hand, the yearly average cost of medical treatment per patient has been found as
€6080,16. The incremental cost effectiveness ratio (ICER) for Intrathecal Baclofen
Therapy versus Medical Treatment for severe spasticity analysed as 89,33€ per
“ashworth score”. CONCLUSIONS: Intrathecal Baclofen Therapy is a cost-effective
technology for the severe spasticity patients compared to the medical treatment
for severe spasticity in Turkey.
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OBJECTIVES: The FAME Study is an international multicenter randomized clinical
trial (n1,005), which demonstrated a significant improvement in health outcomes
for patients with multivessel coronary artery disease undergoing percutaneous
coronary intervention (PCI) guided by fractional flow reserve measurement (FFR)
compared to PCI guided by angiography alone. We performed a cost-effectiveness
analysis along the FAME trial to estimate the cost effectiveness of FFR in France and
Belgium and compared the results with those of other European countries.
METHODS: We used original patient-level data of the FAME study (Tonino et al.,
NEJM 2009) to estimate resource consumption, which was valued using prices from
French and Belgian price lists and DRG catalogues (2010 values). Utilities were
measured with EQ-5D based on French time trade-off and Torrance-transformed
Belgian visual analogue scale (VAS) weights. We adopted a societal perspective and
a one-year time horizon (i.e., follow-up of the FAME Study). Variability was exam-
ined using one-way sensitivity analysis and bootstrap resampling (n5000). Re-
sults are expressed in incremental costs (EUR) and incremental QALYs. RESULTS:
In both countries, FFR slightly improved QALYs (p0.05) at significantly lower costs
(p0.05). Cost savings reached approximately 900 EUR/patient for both countries.
For both countries, bootstrap analysis showed that FFR was cost saving in50% of
all bootstrap samples and cost effective in 90% when using a cost-effectiveness
threshold of 50,000 EUR/QALY. The most influential cost components were prices
for DES and FFR pressure wires. Cost-savings in France and Belgium are higher than
recently presented results for Germany, the UK and Italy, where FFR is cost saving
with savings ranging from 300-600 EUR/patient. CONCLUSIONS: In the context of
the health care systems of Belgium and France, FFR-guided PCI is cost saving (dom-
inant) in patients with multivessel coronary artery disease. These results are ro-
bust and in line with those of other European countries.
PMD41
DRUG ELUTING STENT (DES) VERSUS BARE METAL STENT (BMS) ON CLINICAL,
HUMANISTIC AND ECONOMIC OUTCOMES: A 12-MONTH PROSPECTIVE
OBSERVATIONAL STUDY
Lee V1, Yan B2, Lau JC1, Tang WK1, Yu CM2
1The Chinese University of Hong Kong, Shatin, N.T Hong Kong, Hong Kong, 2The Chinese
University of Hong Kong, Shatin, Hong Kong
OBJECTIVES: An ongoing 2-year local prospective study to compare clinical, hu-
manistic and economic outcomes of Drug Eluting Stents (DES) and Bare Metal
Stents (BMS). METHODS: All patients receiving DES or BMS placement in Prince of
Wales Hospital in Hong Kong within the period of September 2009 to March 2010
were recruited and followed for 12 months. Clinical outcome was measured by
occurrence of major adverse cardiac events (MACE). EQ-5D questionnaire, with
visual analog scale (VAS), was used to assess patients’ health-related quality of life.
The questionnaire was administered by patients before procedure, at 6 month and
12 month. Cost of index procedure and follow-up were recorded and cost per QALY
of DES over BMS was used to evaluate cost-effectiveness of DES. Subgroup analysis
was performed on patients with diabetes mellitus (DM). RESULTS: 325 patients
were enrolled (n210 for DES and n115 for BMS), with balanced baseline charac-
teristics. MACE was significantly less common in DES group (n10, 4.8% vs n14,
12.2%; OR0.361, 95% Cl0.155 to 0.841). The increase in utility score at 12 month
was 0.22 for DES group and 0.17 for BMS group (p0.294). Aggregate 12-month cost
was higher in DES group (HK$110,640 68,706 vs HK$99,802 93,420; p0.235). Cost per
QALY gained for DES was HK$184,564. Subgroup analysis showed that cost per
QALY was HK$15,303 in DM patients. Subsidizing DM patients to use DES, instead
of BMS, could save up to HK$6,370,000 annually for Hospital Authority. (1US$ 7.8
HK$) CONCLUSIONS: DES was shown to be superior to BMS in clinical outcome.
Even with higher procedural cost in DES group, the lower follow-up cost resulted in
gradually smaller difference in aggregate cost. DES was more cost-effective than
BMS, especially in DM patients. Subsidizing DM patients to use DES would be cost-
saving and lead to better clinical outcome.
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OBJECTIVES: Neutropaenia, a chemotherapy-related adverse event, is graded in
terms of severity and can have different relative effects on health and resource use.
For advanced colorectal cancer (CRC) patients on irinotecan-based chemotherapy,
UGT1A1 testing can stratify populations into different risk groups to potentially
reduce the incidence of febrile neutropaenia, which may also impact on healthcare
resources. High-risk patients can be prescribed lower irinotecan doses to reduce
febrile neutropaenia. Two previous economic evaluations of UGT1A1 testing fo-
cussed on reducing grade 3&4 neutropaenia. This study aimed to assess the cost-
effectiveness of UGT1A1 testing to reduce the incidence of irinotecan-related fe-
brile neutropaenia. METHODS: An economic model of UGT1A1 testing to predict
febrile neutropaenia compared to standard care was developed over a lifetime
horizon from the UK NHS perspective. Treatment pathways were informed by a
national survey of CRC experts (n44). Model inputs were identified from: a micro-
costing observational study (n48 patients), CRC expert (n55) elicitation and pub-
lished literature. RESULTS: UGT1A1 testing was cost-saving and resulted in lower
incidence of febrile neutropaenia. For a cohort of 100 patients, the test was esti-
mated to save £17,700, avoid 0.4 febrile neutropaenic episodes, gain 0.006 life-years
and 0.007 QALYs. The likelihood that the test was cost-effective was 94% at a
threshold of £25,000 per QALY gained. Sensitivity analysis (probabilistic and one-
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